Steven Cohen Gritstone Bio, Inc. Transaction History

Point72 Asset Management, L.P.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.96 - $2.9 $1.76 Million - $2.61 Million	-900,000 Reduced 22.64%	3,074,867 $7.9 Million
Q4 2023 Feb 14, 2024	SELL	$1.28 - $2.85 $2.5 Million - $5.56 Million	-1,950,000 Reduced 32.91%	3,974,867 $8.11 Million
Q3 2023 Nov 14, 2023	SELL	$1.19 - $2.26 $1.96 Million - $3.73 Million	-1,648,813 Reduced 21.77%	5,924,867 $10.2 Million
Q2 2023 Aug 14, 2023	SELL	$1.66 - $3.03 $176,270 - $321,746	-106,187 Reduced 1.38%	7,573,680 $14.8 Million
Q4 2022 Feb 14, 2023	BUY	$2.17 - $3.92 $16.7 Million - $30.1 Million	7,679,867 New	7,679,867 $26.5 Million
Q2 2021 Aug 16, 2021	SELL	$8.13 - $10.2 $1.41 Million - $1.77 Million	-174,000 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$4.07 - $27.11 $708,180 - $4.72 Million	174,000 New	174,000 $1.64 Million
Q4 2018 Feb 14, 2019	SELL	$11.61 - $31.1 $116,100 - $311,000	-10,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$14.24 - $14.24 $142,400 - $142,400	10,000 New	10,000 $142,000

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.